Eidos Therapeutics closes $64mm Series B round
Eidos Therapeutics Inc. raised $64mm in a Series B financing round led by RA Capital Management (adds board seat). The company's parent, BridgeBio Pharma, and new investors Janus Henderson, Viking Global Investors, Aisling Capital (adds board seat), Perceptive Advisors, Cormorant Asset Management, and Amzak Health Investors also participated.
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com